As per the research report, the size of the Europe Spine Biologics Market is valued at USD 688.38 million in 2023 and estimated to be growing at a CAGR of 4.3%, to reach USD 849.67 million by 2028 during the forecast period 2023 to 2028.
Spine biologics are used during spine fusion surgery for the treatment of spinal deformities such as trauma, tumors, degenerative disc disease, and spinal cord injuries by stimulating bone growth formation through the inflammatory stage, repair stage, and remodeling stage. Biologics help in faster recovery and activate cellular growth. Therefore, the surge in the number of spinal fusion surgeries has fueled the adoption of biologics.
Spine Biologics market is growing due to advancement in technology as well as demand for better minimally surgical procedures, which make it more convenient for both the patient and doctor. Factors such as a rise in the prevalence of diseases due to the aging population and increased government funding are also driving the overall market. The major factors restraining the growth of the market are the high healthcare costs for such procedures, lack of expert professionals and unfavorable reimbursement scenarios.
This research report on the Europe Spine Biologics Market has been segmented and sub-segmented into the following categories:
By Product Type:
By Surgery Type:
The bone grafts substitute segment accounted for a major share of the market.
Key players operating in the Europe Spine Biologics Market profiled in this report are Alphatec Holdings, Inc., Depuy Synthes (Johnson & Johnson), Exactech, Inc., Globus Medical, Inc., Medtronic plc, NuVasive, Inc., Orthofix International N.V., RTI Surgical, Inc., SeaSpine, and Zimmer Biomet Holdings, Inc.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]